CV Sciences (CVSI) EPS (Diluted) Growth (3y) (2020 - 2026)
CV Sciences (CVSI) EPS (Diluted) Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 15.17% |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 3.25% |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 2.66% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 11.56% |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -35.09% |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 13.29% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 36.48% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | CV Sciences | 4.10 Mn | 3.84 Mn | 1.45 Mn | 23.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.50% |
| Mar 31, 2026 | -27.89% |
| Dec 31, 2025 | 27.08% |
| Sep 30, 2025 | 33.46% |
| Jun 30, 2025 | 62.28% |
| Mar 31, 2025 | 68.03% |
| Dec 31, 2024 | 68.17% |
| Sep 30, 2024 | -89.68% |
| Jun 30, 2024 | 53.08% |
| Mar 31, 2024 | 49.51% |
| Dec 31, 2023 | 60.70% |
| Sep 30, 2023 | 54.93% |
| Jun 30, 2023 | 43.53% |
| Mar 31, 2023 | 39.46% |
| Dec 31, 2022 | 37.40% |
| Sep 30, 2022 | 26.77% |
| Jun 30, 2022 | -66.27% |
| Mar 31, 2022 | 43.17% |
| Dec 31, 2021 | -73.71% |
| Sep 30, 2021 | -26.26% |